Literature DB >> 19291800

Characterization of circulating tumor cells by fluorescence in situ hybridization.

Joost F Swennenhuis1, Arjan G J Tibbe, Rianne Levink, Ronald C J Sipkema, Leon W M M Terstappen.   

Abstract

Tumor cells in blood of patients with metastatic carcinomas have been associated with poor survival prospects. Further characterization of these cells may provide further insights into the metastatic process. Circulating Tumor Cells (CTC) were enumerated in 7.5 mL of blood with the CellSearch system. After enumeration of Cytokeratin+, CD45-, nucleated cells, the cells are fixed in the cartridge while maintaining their original position. Cartridges were hybridized with FISH probes against the centromeric regions of chromosome 1, 7, 8, and 17. Next fluorescence images of the FISH probes of the previous identified CTC were acquired. Leukocytes surrounding the CTC were used as internal controls. The number of copies of chromosome 1, 7, 8, and 17 could be determined in 118 CTC containing blood samples from 59 metastatic prostate cancer patients. The samples contained a total of 21,751 CTC (mean 184, median 16, SD 650). Chromosome counts were obtained in 61% of the relocated CTC. On an average, these CTC contained 2.8 copies of chromosome 1, 2.7 copies of chromosome 7, 3.1 copies of chromosome 8, and 2.3 copies of chromosome 17. CTC in which no chromosome count was obtained most likely underwent apoptosis indicated by the expression of M30. In 6/59 patients only diploid CTC were detected these samples, however, only contained 1-5 CTC. Heterogeneity in the chromosomal abnormalities was observed between CTC of different patients as well as among CTC of the same patient. Cytogenetic composition of CTC can be reliably assessed after they have been identified by the CellSearch system. The majority of CTC in hormone refractory prostate cancer are aneuploid confirming that they indeed are cancer cells. An extensive heterogeneity in the copy number of each of the chromosomes was observed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19291800     DOI: 10.1002/cyto.a.20718

Source DB:  PubMed          Journal:  Cytometry A        ISSN: 1552-4922            Impact factor:   4.355


  51 in total

1.  Effect of circulating tumor cells combined with negative enrichment and CD45-FISH identification in diagnosis, therapy monitoring and prognosis of primary lung cancer.

Authors:  Yang-Yang Chen; Guo-Bin Xu
Journal:  Med Oncol       Date:  2014-11-01       Impact factor: 3.064

Review 2.  Challenges in circulating tumor cell detection by the CellSearch system.

Authors:  Kiki C Andree; Guus van Dalum; Leon W M M Terstappen
Journal:  Mol Oncol       Date:  2015-12-25       Impact factor: 6.603

Review 3.  Molecular analysis of circulating tumour cells-biology and biomarkers.

Authors:  Matthew G Krebs; Robert L Metcalf; Louise Carter; Ged Brady; Fiona H Blackhall; Caroline Dive
Journal:  Nat Rev Clin Oncol       Date:  2014-01-21       Impact factor: 66.675

Review 4.  Circulating tumor cell isolation, culture, and downstream molecular analysis.

Authors:  Sandhya Sharma; Rachel Zhuang; Marisa Long; Mirjana Pavlovic; Yunqing Kang; Azhar Ilyas; Waseem Asghar
Journal:  Biotechnol Adv       Date:  2018-03-17       Impact factor: 14.227

Review 5.  Dormancy in solid tumors: implications for prostate cancer.

Authors:  Nazanin S Ruppender; Colm Morrissey; Paul H Lange; Robert L Vessella
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

6.  What's new on circulating tumor cells? A meeting report.

Authors:  Evi S Lianidou; Dimitris Mavroudis; Georgia Sotiropoulou; Sophia Agelaki; Klaus Pantel
Journal:  Breast Cancer Res       Date:  2010-07-23       Impact factor: 6.466

Review 7.  The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells.

Authors:  Huiying Liu; Xiaofeng Zhang; Jun Li; Bin Sun; Haihua Qian; Zhengfeng Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-26       Impact factor: 4.553

8.  Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer.

Authors:  Christin Gasch; Theresa Oldopp; Oliver Mauermann; Tobias M Gorges; Antje Andreas; Cornelia Coith; Volkmar Müller; Tanja Fehm; Wolfgang Janni; Klaus Pantel; Sabine Riethdorf
Journal:  Mol Oncol       Date:  2016-07-22       Impact factor: 6.603

Review 9.  Circulating Tumor Cell Isolation and Analysis.

Authors:  J Zhang; K Chen; Z H Fan
Journal:  Adv Clin Chem       Date:  2016-04-21       Impact factor: 5.394

10.  Circulating tumor cell analysis: technical and statistical considerations for application to the clinic.

Authors:  Alison L Allan; Michael Keeney
Journal:  J Oncol       Date:  2009-12-13       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.